SCHEMBL6841185

SCHEMBL6841185

Cc1nc(-c2cccnc2-c2cc(F)cc(S(N)(=O)=O)c2)cs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES2 Q9H7Z7 1/20 0.41
SCN9A Q15858 3/20 0.39
GFER P55789 1/20 0.39
PTGS2 P35354 2/20 0.39
BLM P54132 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ALDH1A1 P00352 4/20 0.36
MAPT P10636 3/20 0.36
HPGD P15428 2/20 0.36
USP2 O75604 1/20 0.36
GAA P10253 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HTT P42858 4/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6749607 0.85 SCN9A (0.40) PTGES2SCN9AGFERPTGS2BLM
SCHEMBL6835041 0.84 TGFBR1 (0.41) PTGS2CA1CA2
SCHEMBL6835212 0.83 CA1 (0.44) PTGS2BLMCA1CA2
SCHEMBL6840807 0.83 TGFBR1 (0.45) PTGS2CA1CA2
SCHEMBL6834757 0.82 CA1 (0.45) PTGES2SCN9APTGS2BLMCA1
SCHEMBL6718990 0.81 SCN9A (0.44) PTGES2SCN9APTGS2BLMALDH1A1
SCHEMBL6841538 0.80 CA1 (0.45) PTGS2BLMCA1CA2GAA
SCHEMBL6833679 0.80 PTGS2 (0.49) PTGS2CA1CA2
SCHEMBL6834914 0.80 CA1 (0.41) PTGS2CA1CA2
SCHEMBL6837797 0.78 PTGS2 (0.52) PTGS2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGES2 8/4885SCN9A 4450/4885GFER 756/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGES2 8/4885SCN9A 4450/4885GFER 756/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGES2 8/4885SCN9A 4450/4885GFER 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.